Drug Profile
Research programme: gastrointestinal disease therapeutics - Auriga/Degussa
Alternative Names: Gastrointestinal disease therapeutics - Auriga/DegussaLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Auriga Laboratories; Degussa
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammatory bowel diseases
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammatory-bowel-disease in Germany (PO, Controlled release)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammatory-bowel-disease in USA (PO, Controlled release)
- 22 Aug 2006 Preclinical trials in Inflammatory bowel disease in Germany (PO)